Abstract
The publication of the International Conference of Harmonization (ICH) Q8, Q9, and Q10 guidelines paved the way for the standardization of quality after the Food and Drug Administration issued current Good Manufacturing Practices guidelines in 2003. “Quality by Design”, mentioned in the ICH Q8 guideline, offers a better scientific understanding of critical process and product qualities using knowledge obtained during the life cycle of a product. In this scope, the “knowledge space” is a summary of all process knowledge obtained during product development, and the “design space” is the area in which a product can be manufactured within acceptable limits. To create the spaces, artificial neural networks (ANNs) can be used to emphasize the multidimensional interactions of input variables and to closely bind these variables to a design space. This helps guide the experimental design process to include interactions among the input variables, along with modeling and optimization of pharmaceutical formulations. The objective of this study was to develop an integrated multivariate approach to obtain a quality product based on an understanding of the cause–effect relationships between formulation ingredients and product properties with ANNs and genetic programming on the ramipril tablets prepared by the direct compression method. In this study, the data are generated through the systematic application of the design of experiments (DoE) principles and optimization studies using artificial neural networks and neurofuzzy logic programs.
Similar content being viewed by others
REFERENCES
Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151–85.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Pharmaceutical Development, Q8(R2); 2009.
Arling ER, Dowling ME, Frankel PA. In: Gad SC, editor. Process analytical technology. pharmaceutical manufacturing handbook regulations and quality. New York: Wiley; 2008.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Quality Risk Management, Q9; 2005.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Pharmaceutical Quality Systems, Q10; 2008.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Development and Manufacture Drug Substances Report Q11; 2008 (endorsed).
Zhao C, Jain A, Hailemariam L, Suresh P, Akkisetty P, Joglekar G, Venkatasubramanian V, Reklaitis VG, Morris K, Basu P. Toward intelligent decision support for pharmaceutical product development. JPI. 2006;1:23–35.
Colbourn EA, Rowe CR. Neural computing and formulation optimization. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. New York: Informa Healthcare; 2007. p. 2399–412.
Krogh A. What are artificial neural networks? Nat Biotechnol. 2008;26:195–7.
Armstrong NA, James KC. Pharmaceutical experimental design and interpretation. UK: Taylor and Francis Ltd; 1996.
Rowe RC, Roberts JR. Intelligent software for product formulation. Chapter 5. Neural networks, genetic algorithms and fuzzy logic. USA: Taylor and Francis Ltd; 1998. p. 55–75.
DeMatas M, Shao Q, Shukla R. Artificial intelligence the key to process understanding. Pharmaceut Tech Eur. 2007;19:1.
The European Pharmacopoeia (online). EU;2010.
Martindale W. Martindale, The Extra Pharmacopeia, thirty third edn. The Pharm. Press, London; 1996.
INForm Intelligent Formulation. Intelligensys Ltd., UK; 2009.
The United States Pharmacopeia, NF 19. United States Pharmacopeial Convention, INC.,Philadelphia, PA; 2000.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Methodology, Q2(R1); 1996.
Shao Q, Rowe RC, York P. Investigation of an artificial intelligence technology—model trees novel applications for an immediate release tablet formulation database. Eur J Pharm Sci. 2007;31:137–44.
Ritchie MD, White BC, Parker JS, Hahn LW, Moore JH. Optimization of neural network architecture using genetic programming improves detection and modeling of gene-gene Interactions in studies of human diseases. BMC Bioinforma. 2003;4:1–14.
Shao Q, Rowe RC, York P. Comparision of neurofuzzy logic and neural networks in modeling experimental data of an immediate release tablet formulation. Eur J Pharm Sci. 2006;28:394–404.
Bourquin J, Schmidli H, Hoogevest PV, Leuenberger H. Comparison of artificial neural networks (ANN) with classical modelling techniques using different experimental designs and data from a galenical study on a solid dosage form. Eur J Pharm Sci. 1998;6:287–300.
Colbourn EA, Roskilly SJ, Rowe RC, York P. Modelling formulations using gene expression programming—a comparative analysis with artificial neural networks. Eur J Pharm Sci. 2011;44:366–74.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aksu, B., Paradkar, A., de Matas, M. et al. Quality by Design Approach: Application of Artificial Intelligence Techniques of Tablets Manufactured by Direct Compression. AAPS PharmSciTech 13, 1138–1146 (2012). https://doi.org/10.1208/s12249-012-9836-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-012-9836-x